Formulation and characterization of nanoparticles loaded with curcumin and amantadine as a promising neuroprotective agent

Aksa Alex, Apsara Unni, Gayathri Kumararaja, DOI: 10.46793/BiolNyss.16.1.23A

Abstract


Parkinson's Disease (PD) is regarded as the second most common neurodegenerative disease and is characterized by observable motor dysfunction and loss of dopaminergic neurons. To date, there is no cure for PD, nor the treatment that stops its progression. Nanotechnology is very useful for controlling drug release, thus improving drug pharmacokinetic and pharmacodynamic properties. In this study, we fabricated curcumin- and amantadine-loaded nanoparticles using bovine serum albumin (BSA) as a nanocarrier using the desolvation method. Encapsulating curcumin and amantadine were beneficial in improving its aqueous solubility and bioavailability. The prepared nanoparticles had the particle size and zeta potential of 257 nm and -29 mV, respectively. The in vitro neuroprotective effect was determined using SHSY5Y cell lines through the MTT assay, which showed strong neuroprotective activity.


Keywords


bovine serum albumin, curcumin, amantadine, desolvation, neuroprotective activity

Full Text:

PDF

References


Alonso, M.J. & Couvreur, P. (2012). Historical view of the design and development of nanocarriers for overcoming biological barriers. In: Nanostructured Biomaterials for Overcoming Biological Barriers (pp. 3-36). UK, Cambridge: The Royal Society of Chemistry.

Cheng, K.K., Yeung, C.F., Ho, S.W., Chow, S.F., Chow, A.H., & Baum, L. (2013). Highly stabilized curcumin nanoparticles tested in an in vitro blood–brain barrier model and in Alzheimer’s disease Tg2576 mice. The AAPS journal, 15, 324-336. doi: 10.1208/s12248-012-9444-4.

Dorsey, E.R. & Bloem, B.R. (2018). The Parkinson pandemic - a call to action. JAMA neurology, 75(1), 9-10. doi: 10.1001/jamaneurol.2017.3299.

Espay, A.J., Ostrem, J.L., Formella, A.E., & Tanner, C.M. (2024). Extended-release amantadine for OFF-related dystonia in Parkinson's disease. Parkinsonism & Related Disorders, 122, 106088. https://doi.org/10.1016/j.parkreldis.2024.106088

Fink, K., Nitsche, A., Neumann, M., Grossegesse, M., Eisele, K.H., & Danysz, W. (2021). Amantadine inhibits SARS-CoV-2 in vitro. Viruses, 13(4), 539.

Kim, T.H., Jiang, H.H., Youn, Y.S., Park, C.W., Tak, K.K., Lee, S., Kim, H., Jon, S., Chen, X., & Lee, K.C. (2011). Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. International Journal of Pharmaceutics, 403(1-2), 285-291. doi: 10.1016/j.ijpharm.2010.10.041.

Gayathri, K., Bhaskaran, M., Selvam, C., & Thilagavathi, R. (2023). Nano formulation approaches for curcumin delivery-a review. Journal of Drug Delivery Science and Technology, 82, 104326. https: //doi.org/10.1016/j.jddst.2023.104326.

Maksymiuk, A.W., Tappia, P.S., Bux, R.A., Moyer, D., Huang, G., Joubert, P., Miller, D.W., Ramjiawan, B., & Sitar, D.S. (2021). Use of amantadine in the evaluation of response to chemotherapy in lung cancer: A pilot study. Future Science OA, 7(4), FSO679. doi: 10.2144/fsoa-2020-0176.

Mourtas, S., Lazar, A.N., Markoutsa, E., Duyckaerts, C., & Antimisiaris, S.G. (2014). Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. European Journal of Medicinal Chemistry, 80, 175-183. doi: 10.1016/j.ejmech.2014.04.050.

Nair, P., Malhotra, A., & Dhawan, D.K. (2015). Curcumin and quercetin trigger apoptosis during benzo(a)pyrene-induced lung carcinogenesis. Molecular and Cellular Biochemistry, 400, 51-56. doi: 10.1007/s11010-014-2261-6.

Nazari, Q.A., Takada-Takatori, Y., Hashimoto, T., Imaizumi, A., Izumi, Y., Akaike, A., & Kume, T. (2014). Potential protective effect of highly bioavailable curcumin on an oxidative stress model induced by microinjection of sodium nitroprusside in mice brain. Food & Function, 5(5), 984-989. doi: 10.1039/c4fo00009a.

Parkinson, J. (2002). An essay on the shaking palsy. The Journal of neuropsychiatry and clinical neurosciences, 14(2), 223-236. doi: 10.1176/jnp.14.2.223.

Parkinson’s News Today (2021). Parkinson’s Disease Statistics. Retrieved from https://parkinsonsnewstoday.com/parkinsons-disease-statistics (accessed on 8 December 2021).

Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkmann, J., Schrag, A.E., & Lang, A.E. (2017). Parkinson disease. Nature reviews Disease Primers, 3(1), 1-21. https://doi.org/10.1038/nrdp.2017.13

Rascol, O., Fabbri, M., & Poewe, W. (2021). Amantadine in the treatment of Parkinson's disease and other movement disorders. The Lancet Neurology, 20(12), 1048-1056. doi: 10.1016/S1474-4422(21)00249-0.

Simon, D.K., Tanner, C.M., & Brundin, P. (2020). Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clinics in Geriatric Medicine, 36(1), 1-12. doi: 10.1016/j.cger.2019.08.002.

Staničová, J., Miškovský, P., & Šutiak, V. (2001). Amantadine: an antiviral and antiparkinsonian agent. Veterinární medicína, Czech Academy of Agricultural Sciences, 46(9), 244-256.

Takahashi, M., Uechi, S., Takara, K., Asikin, Y., & Wada, K. (2009). Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. Journal of Agricultural and Food Chemistry, 57(19), 9141-9146. doi: 10.1021/jf9013923.

Tonda-Turo, C., Origlia, N., Mattu, C., Accorroni, A., & Chiono, V. (2018). Current limitations in the treatment of Parkinson's and Alzheimer's diseases: state-of-the-art and future perspective of polymeric carriers. Current Medicinal Chemistry, 25(41), 5755-5771. doi: 10.2174/0929867325666180221125759.

Tsai, Y.M., Chien, C.F., Lin, L.C., & Tsai, T.H. (2011). Curcumin and its nanoformulation: the kinetics of tissue distribution and blood–brain barrier penetration. International Journal of Pharmaceutics, 416(1), 331-338. doi: 10.1016/j.ijpharm.2011.06.030.

Yadav, V.K., Dhanasekaran, S., Choudhary, N., Nathiya, D., Thakur, V., Gupta, R., Pramanik, S., Kumar, P., Gupta, N., & Patel, A. (2025). Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives. Frontiers in Medicine, 12, 1535682. doi:10.3389/fmed.2025.1535682.

Young, N.A., Bruss, M.S., Gardner, M., Willis, W.L., Mo, X., Valiente, G.R., Cao, Y., Liu, Z., Jarjour, W.N., & Wu, L.C. (2014). Oral administration of nano-emulsion curcumin in mice suppresses inflammatory-induced NFκB signaling and macrophage migration. PloS One, 9(11), e111559. doi: 10.1371/journal.pone.0111559.


Refbacks

  • There are currently no refbacks.